Prevention of decline in cognition after stroke trial
| ISRCTN | ISRCTN85562386 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN85562386 |
| Secondary identifying numbers | Version 1.0 |
- Submission date
- 03/08/2009
- Registration date
- 23/09/2009
- Last edited
- 19/01/2017
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Mental and Behavioural Disorders
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Background and study aims
A stroke occurs when the blood supply to part of the brain is cut off, either due to a blood clot (an ischaemic stroke) or a blood vessel bursting (a haemorrhagic stroke). Stroke can lead to cognitive decline and dementia. Intensive lowering of blood pressure and/or lipids (LDL-cholesterol) may reduce the risk of dementia after stroke. The aim of this study is to find out whether intensive blood pressure and/or lipid lowering are better than moderate blood pressure and/or lipid lowering to prevent cognitive decline after stroke.
Who can participate?
Patients who have had an ischaemic or haemorrhagic stroke in the last three to seven months.
What does the study involve?
Participants with ischaemic stroke are randomly allocated to either moderate or intensive blood pressure lowering treatment and to either moderate or intensive lipid lowering treatment. Participants with haemorrhagic stroke are randomly allocated to either moderate or intensive blood pressure lowering treatment. The study is testing treatment strategies, not individual drugs.
What are the possible benefits and risks of participating?
Not provided at time of registration
Where is the study run from?
Nottingham University Hospitals NHS Trust (UK)
When is the study starting and how long is it expected to run for?
January 2010 to January 2018
Who is funding the study?
1. The Stroke Association (UK)
2. The Alzheimer's Society (UK)
Who is the main contact?
Prof. Philip Bath
Philip.Bath@nottingham.ac.uk
Contact information
Prof Philip Bath
Scientific
Scientific
Division of Stroke Medicine
Institute of Neuroscience
Clinical Sciences Building
City Hospital Campus
Hucknall Road
Nottingham
NG5 1PB
United Kingdom
| Phone | +44 (0)115 8231765 |
|---|---|
| Philip.Bath@nottingham.ac.uk |
Study information
| Study design | Multicentre prospective randomised open-label blinded end-point controlled partial-factorial phase IV trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details to request a patient information sheet |
| Scientific title | Prevention Of Decline in Cognition After Stroke Trial (PODCAST): a factorial randomised controlled trial of intensive versus guideline (moderate) lowering of blood pressure and lipids |
| Study acronym | PODCAST |
| Study objectives | To study if intensive blood pressure and/or lipid lowering post stroke, is better than moderate blood pressure and/or lipid lowering, to prevent cognitive decline after stroke. |
| Ethics approval(s) | Nottingham Research Ethics Committee 1, 24/07/2009 |
| Health condition(s) or problem(s) studied | Cognitive impairment after stroke |
| Intervention | The trial will assess whether intensive blood pressure lowering (systolic blood pressure less than 125 mmHg) and lipid lowering (low density lipoprotein [LDL]-cholesterol less than 2.0 mmol/L) is better than moderate blood pressure lowering (systolic blood pressure less than 140 mmHg) and cholesterol lowering (LDL-cholesterol less than 3.0 mmol/L). Participants with ischaemic stroke will be randomised to both the blood pressure and lipid lowering arms; participants with haemorrhagic stroke will be randomised only to the blood pressure lowering arm. The study will test management strategies and not individual drugs. Algorithms taking account of 'National Institute of Clinical Excellence, UK Guidelines', relating to stroke, hypertension, lipids and Type 2 Diabetes will aid investigators in treatment decision-making using standard antihypertensive and lipid lowering drugs so that participants are treated as randomised. The total duration of the trial is 8 years and follow up for participants will range from 1 - 8 years depending on the time of enrolment. The trial intervention will be for the same duration. |
| Intervention type | Other |
| Primary outcome measure | Comparison of cognition (Addenbrooke's Cognitive Examination extended to include death) between 'intensive' and 'moderate' BP/lipid lowering groups, measured at baseline, 6, 18, 30, 42, 54, 66, 78, 90 and 96 months. |
| Secondary outcome measures | For each of BP-lowering and lipid-lowering arms, comparison between 'intensive' and 'moderate' groups: 1. Dementia: measured at 6, 18, 30, 42, 54, 66, 78, 90 and 96 months - 1.1. Using alzheimers disease (AD) - National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) and vascular dementia (VaD) - National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherché et l'Enseignement en Neurosciences (NINDS-AIREN) 1.2. With/without recurrent stroke 2. Cognition: all tests at 6, 18, 30, 42, 54, 66, 78, 90 and 96 months, except telephone-administered mini-mental state examination (tMMSE) and Telephone Interview for Cognitive Status (TICS-M) done at 0, 12, 24, 36, 48, 70 and 84 months over the telephone 2.1. Global - mini-mental state examination (MMSE), tMMSE, TICS 2.2. Association - trail making A/B 2.3. STROOP test 2.4. Cognitive decline with/without recurrent stroke 2.5. Ordinal cognition (MMSE greater than 28/23 - 28/10 - 22/less than 10/dementia/dead) 2.6. Informant (IQCODE) 3. Quality of life - EuroQoL, informant (DEMQoL), measured at baseline, 6, 18, 30, 42, 54, 66, 78, 90 and 96 months 4. Depression (Zung), measured at baseline, 6, 18, 30, 42, 54, 66, 78, 90 and 96 months 5. Dependency (modified Rankin Scale [mRS]), measured at baseline, 6, 18, 30, 42, 54, 66, 78, 90 and 96 months 6. Disability (Barthel Index [BI]), measured at baseline, 6, 18, 30, 42, 54, 66, 78, 90 and 96 months 7. Stroke recurrence, measured at baseline and every six months until the end of the trial 8. Myocardial infarction, measured every six months until the end of the trial 9. Composite vascular events (non-fatal stroke, non-fatal MI, fatal vascular), measured every six months until the end of the trial 10. Stroke: fatal/severe non-fatal/mild/transient ischaemic attack [TIA]/none, measured at baseline and every six months until the end of the trial 11. Myocardial infarction: fatal/non-fatal/angina/none, measured at baseline and every six months until the end of the trial 12. Vascular: fatal/non-fatal/none, measured at baseline and every six months until the end of the trial 13. New diabetes, measured at baseline, 6, 18, 30, 42, 54, 66, 78, 90 and 96 months 14. New atrial fibrillation, measured at baseline, 6, 18, 30, 42, 54, 66, 78, 90 and 96 months 15. Residence (home, institution), care package, informal family support, measured at baseline, 6, 18, 30, 42, 54, 66, 78, 90 and 96 months 16. Blood pressure (systolic BP, diastolic BP, pulse pressure, rate-pressure product), measured at baseline, 6, 18, 30, 42, 54, 66, 78, 90 and 96 months 17. Lipids (total cholesterol [TC], triglycerides [TG], HDL, calculated LDL), measured at baseline, 6, 18, 30, 42, 54, 66, 78, 90 and 96 months 18. Neuroimaging (in a subset of participants), measured at baseline and at 3 years |
| Overall study start date | 01/01/2010 |
| Completion date | 01/01/2018 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Senior |
| Sex | Both |
| Target number of participants | 3400 participants (600 in the start-up phase and 2800 in the main phase) |
| Key inclusion criteria | 1. Age greater than 70 years and telephone-administered mini-mental state examination (MMSE) greater than 16; or aged greater than 60 years and telephone-MMSE 17 - 19, either sex 2. Functionally independent (modified Rankin Scale [mRS] 0 - 2) 3. Ischaemic stroke (any cortical Oxfordshire Community Stroke Project [OCSP]/Trial of ORG 10172 in Acute Stroke Treatment [TOAST] type) or primary intracerebral haemorrhage (cortical or basal ganglia) 4. Three to seven months post-event (to allow cognitive, neurological, blood pressure [BP] and lipid stabilisation, but avoid attrition) 5. Systolic BP 125 - 170 mmHg 6. Total cholesterol 3 - 8 mmol/l 7. Presence of a reporter: partner, sibling, child, friend (for Informant Questionnaire of Cognitive Decline [IQCODE]/Dementia Quality of Life [DEMQoL]) 8. Capacity and willingness to give consent |
| Key exclusion criteria | 1. Participants not meeting inclusion criteria 2. Subarachnoid haemorrhage 3. Secondary intracranial haemorrhage (trauma, arteriovenous malformation [AVM], cavernoma) 4. Posterior circulation ischaemic stroke 5. Posterior circulation haemorrhage 6. No computed tomography (CT)/magnetic resonance imaging (MRI) during index stroke 7. Inability to give consent or do study measures, e.g. severe dysphasia, weakness of dominant arm 8. Severe hypertension (systolic BP greater than 170 mmHg) 9. Definite need for 'intensive' BP control 10. Severe hypercholesterolemia (total cholesterol [TC] greater than 8 mmol/l) 11. Definite need for 'high intensity' statin or ezetimibe 12. Definite need for a cholinesterase inhibitor 13. Familial stroke associated with dementia, e.g. cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL) 14. Chronic renal failure: glomerular filtration rate (GFR) less than 50 15. Liver disease, alanine aminotransferase (ALT) greater than 60 16. Ongoing participation in trials involving drug and/or devices, or within the last 3 months |
| Date of first enrolment | 01/01/2010 |
| Date of final enrolment | 01/01/2018 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
Institute of Neuroscience
Notttingham
NG5 1PB
United Kingdom
NG5 1PB
United Kingdom
Sponsor information
The University of Nottingham (UK)
University/education
University/education
c/o Mr Paul Cartledge
Head of Research Grants and Contracts
Research Innovation Services
King's Meadow Campus
Lenton Lane
Nottingham
NG7 2NR
England
United Kingdom
| Phone | +44 (0)115 951 5679 |
|---|---|
| paul.cartledge@nottingham.ac.uk | |
| Website | http://www.nottingham.ac.uk |
"ROR" |
https://ror.org/01ee9ar58 |
Funders
Funder type
Charity
Stroke Association (UK) (ref: TSA2008/09)
Private sector organisation / Associations and societies (private and public)
Private sector organisation / Associations and societies (private and public)
- Location
- United Kingdom
Alzheimer's Society (UK) (ref: TSA 2008/09)
Private sector organisation / Associations and societies (private and public)
Private sector organisation / Associations and societies (private and public)
- Alternative name(s)
- alzheimerssoc
- Location
- United Kingdom
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Protocol article | protocol | 22/11/2013 | Yes | No | |
| Results article | results | 07/11/2015 | Yes | No | |
| Results article | results | 17/01/2017 | Yes | No |
Editorial Notes
19/01/2017: Publication reference added.
04/03/2016: Plain English summary added.
09/11/2015: Publication reference added.
